Amid growing congressional efforts to contain drug costs, Sen. Bernie Sanders (I-Vt.) has accused Catalyst Pharmaceuticals (CPRX) of “fleecing” Americans and “immoral exploitation” by setting a “staggering” price for a recently approved drug used to treat a rare neuromuscular disorder.

In a blistering letter, Sanders accused Catalyst of “corporate greed” for charging a $375,000 list price for Firdapse, which is used to contain Lambert-Eaton myasthenic syndrome, or LEMS. Until December, patients could obtain an unapproved version for free from Jacobus Pharmaceuticals, a small, family-run company, thanks to a compassionate use program overseen by the Food and Drug Administration.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Looks to me like some people at the FDA either did not do their homework on this issue or, perhaps, were influenced to not do their homework. Did they not know how cheaply is was being produced by compounding pharmacies and did they not know, from experience, that when a drug gets “orphan drug” status, its price goes through the roof?

    Perhaps, Senator Sanders should be looking at the FDA and its decision making process regarding “orphan drug” status.

  • Sanders is one of the few elected representatives telling the truth. It is time to control the price gouging and outright fraud of the pharma industry.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy